Document Type : Review Article


1 Ph.D, Biotechnology, Department of Biotechnology, College of Science, University of Tehran.

2 Ph.D, Biotechnology, Department of Biotechnology, College of Science, University of Tehran

3 Reference Health Laboratory, Ministry of Health and Medical Education.



Precision medicine is a medical approach that involves customizing therapy for an individual by using extensive biological and external data. The rapid progress in the disciplines of molecular biology, gene sequencing, machine learning, and related technologies has facilitated the use of precision medicine. This approach utilizes the wealth of comprehensive information obtained from these advancements to improve the decision-making process in clinical treatment for individuals, particularly in real-time scenarios during the progression of a disease. Diabetes mellitus is a significant worldwide health issue, requiring the implementation of novel strategies to enhance patient outcomes. The efficacy of conventional treatment options that use a uniform approach has been shown to be limited in effectively addressing the heterogeneous character of the illness. In recent times, personalized medicine has surfaced as a revolutionary resolution, customizing treatment strategies in accordance with an individual's health attributes, lifestyle choices, and genetic composition. This review underscores the significance of genetic screening in forecasting susceptibility to diabetes and treatment response, while also emphasizing the potential of pharmacogenomics to optimize medication selection.


Main Subjects

1.Lanzarone G, Olivi M. The Prognostic Role of Cytogenetics Analysis in Philadelphia Negative Myeloproliferative Neoplasms. Medicina. 2021;57(8):813. [DOI: 10.3390/medicina57080813].
2.Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478(7367):64-9.
3.Lasho T, Finke C, Hanson C, Jimma T, Knudson R, Ketterling R, et al. SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients. Leukemia. 2012;26(5):1135-7.
4.Killick SB, Wiseman DH, Quek L, Cargo C, Culligan D, Enright H, et al. British Society for Haematology guidelines for the diagnosis and evaluation of prognosis of Adult Myelodysplastic Syndromes. British Journal of Haematology. 2021;194(2):282-93.
5.Grinfeld J, Nangalia J, Baxter E, Wedge D, Angelopoulos N, Cantrill R, et al. Classification and Personalized Prognosis in Myeloproliferative Neoplasms. N Engl J Med. 2018;379:1416-30.
6.Ok CY, Trowell KT, Parker KG, Moser K, Weinberg OK, Rogers HJ, et al. Chronic myeloid neoplasms harboring concomitant mutations in myeloproliferative neoplasm driver genes (JAK2/MPL/CALR) and SF3B1. Modern Pathology. 2021;34(1):20-31.
7.Bruneau J, Molina TJ. WHO classification of tumors of hematopoietic and lymphoid tissues. Hematopathology. 2020:501-5.
8.Rumi E, Pietra D, Pascutto C, Guglielmelli P, Martínez-Trillos A, Casetti I, et al. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood, The Journal of the American Society of Hematology. 2014;124(7):1062-9.
9.Wong WJ, Hasserjian RP, Pinkus GS, Breyfogle LJ, Mullally A, Pozdnyakova O. JAK2, CALR, MPL and ASXL1 mutational status correlates with distinct histological features in Philadelphia chromosome-negative myeloproliferative neoplasms. Haematologica. 2018;103(2):e63.
10.Scott LM. The JAK2 exon 12 mutations: a comprehensive review. American journal of hematology. 2011;86(8):668-76.
11.Wong R, Sun S, Wang H-Y, Broome HE, Murray S, Thorson J. In Frame Calr Exon 9 Mutations: Often Ignored but Potentially Significant. Blood. 2018;132:5480.
12.Zulkeflee RH, Zulkafli Z, Johan MF, Husin A, Islam MA, Hassan R. Clinical and laboratory features of JAK2 V617F, CALR, and MPL Mutations in Malaysian patients with classical myeloproliferative neoplasm (MPN). International journal of environmental research and public health. 2021;18(14):7582.
13.Heppner J, Nguyen LT, Guo M, Naugler C, Rashid-Kolvear F. Incidence of myeloproliferative neoplasms in Calgary, Alberta, Canada. BMC research notes. 2019;12(1):1-5.
14.Kaifie A, Kirschner M, Wolf D, Maintz C, Hänel M, Gattermann N, et al. Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry. Journal of hematology & oncology. 2016;9(1):1-11.
15.Yassin MA, Taher A, Mathews V, Hou H-A, Shamsi T, Tuglular T, et al. Myeloproliferative neoplasms in Asia, including Middle East, Turkey, and Algeria: epidemiological indices and treatment practice patterns from the multinational, multicenter, observational MERGE registry. Blood. 2018;132:5461.
16.Ashorobi D, Gohari P. Essential thrombocytosis. StatPearls [Internet]. 2021.
17.Belcic Mikic T, Pajic T, Sever M. CALR mutations in a cohort of JAK2 V617F negative patients with suspected myeloproliferative neoplasms. Scientific reports. 2019;9(1):1-9.
18.Loghavi S, Bueso-Ramos CE, Kanagal-Shamanna R, Young Ok C, Salim AA, Routbort MJ, et al. Myeloproliferative neoplasms with calreticulin mutations exhibit distinctive morphologic features. American journal of clinical pathology. 2016;145(3):418-27.
19.Lin Y, Liu E, Sun Q, Ma J, Li Q, Cao Z, et al. The Prevalence of JAK2, MPL, and CALR mutations in Chinese patients with BCR-ABL1–negative myeloproliferative neoplasms. American journal of clinical pathology. 2015;144(1):165-71.
20.Kim BH, Cho Y-U, Bae M-H, Jang S, Seo E-J, Chi H-S, et al. JAK2 V617F, MPL, and CALR mutations in Korean patients with essential thrombocythemia and primary myelofibrosis. Journal of Korean medical science. 2015;30(7):882-8.
21.Lieu C-H, Shen Y-J, Lai W-C, Tsai W-H, Hsu H-C. Prevalence of MPL W515L/K mutations in Taiwanese patients with Philadelphia-negative chronic myeloproliferative neoplasms. Journal of the Chinese Medical Association. 2010;73(10):530-2.
22.Akpinar T, Hançer V, Nalçaci M, Diz-Küçükkaya R. Kronik miyeloproliferatif neoplazmlarda MPL W515L/K mutasyonlari. Turk J Hematol. 2013;30:8-12.
23.Shams SF, Ayatollahi H, Sadeghian MH, Afzalaghaee M, Shakeri S, Yazdandoust E, et al. Prevalence of MPL (W515K/L) mutations in patients with negative-JAK2 (V617F) myeloproliferative neoplasm in North-East of Iran. Iranian journal of pathology. 2018;13(4):397.
24.Rabade N, Subramanian P, Kodgule R, Raval G, Joshi S, Chaudhary S, et al. Molecular genetics of BCR-ABL1 negative myeloproliferative neoplasms in India. Indian Journal of Pathology and Microbiology. 2018;61(2):209.
25.Xia D, Hasserjian RP. Molecular testing for JAK 2, MPL, and CALR in myeloproliferative neoplasms. American Journal of Hematology. 2016;91(12):1277-80.